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What this paper adds 
 
What is already known 
• Given the rising prevalence of long term health conditions, it is necessary to explore new 
ways to deliver health care and to support self-management  in order to expand provision of 
care at low cost. 
• There is considerable optimism amongst policy-makers that greater use of digital health 
technologies (‘telehealth’) in combination with new ways of working could transform health 
care delivery, helping the NHS to be sustainable. 
• Evidence about the effectiveness of telehealth interventions is equivocal, with some benefits 
from specific technologies but little evidence of effectiveness in ‘real world’ implementation. 
 
What this study adds 
• This pragmatic trial assessed the effectiveness and cost-effectiveness of an intervention for 
people with high risk of cardiovascular disease which combined the use of a range of digital 
health technologies with telephone support from trained lay health advisors. 
• We found some evidence that the intervention led to modest improvement in overall 
cardiovascular risk for a minority of participants, but had no impact on average risk, 
although it was associated with improvements in specific risk factors and patient 
perceptions of support and access to care. 
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Abstract (online version)  
OBJECTIVES 
To assess whether non-clinical staff can effectively manage people at high risk of cardiovascular 
disease using digital health technologies. 
DESIGN 
Pragmatic, multi-centre, randomised controlled trial.  
SETTING  
Participants recruited from 42 general practices in three areas of England 
PARTICIPANTS 
Between 3 December 2012 and 23 July 2013 we recruited 641 adults aged 40 to 74 years with 10 
year cardiovascular disease risk ≥20%, no previous cardiovascular event, at least one modifiable risk 
factor (systolic BP ≥140; body mass index ≥30; current smoker) and access to telephone, internet 
and email.  
INTERVENTIONS 
Participants individually allocated to intervention (n= 325) or control (n= 316) using automated 
randomisation stratified by site, minimised by practice and baseline risk score. Intervention: The 
Healthlines Service (alongside usual care), comprising regular telephone calls from trained lay health 
advisors following scripts generated by interactive software. Advisors facilitated self-management by 
supporting participants to use online resources to reduce risk factors and sought to optimise 
medication, improve treatment adherence and encourage healthier lifestyles. Control: usual care 
alone.  
MAIN OUTCOME MEASURES 
Primary outcome:  proportion of participants responding to treatment, defined as maintaining or 
reducing their cardiovascular risk after 12 months. Outcomes were collected 6 and 12 months after 
randomisation and analysed masked. Participants were not masked. 
RESULTS 
50.2% (148/295) of intervention group participants responded to treatment compared with 42.6% 
(124/291) in the control group (adjusted odds ratio 1.3; 95% confidence interval 1.0 to 1.9; number 
needed to treat = 13); a difference possibly due to chance (p=0.079). The intervention was 
associated with reductions in BP (difference in mean systolic -2.7 mmHg (-4.7 to -0.6), mean diastolic 
-2.8 (-4.0 to -1.6)); weight (-1.0 kg (-1.8 to -0.3)), and body mass index (-0.4 (-0.6 to -0.1)) but not 
cholesterol (-0.1 (-0.2 to 0.0), smoking status (adjusted OR 0.4 (0.2 to 1.0)), or overall cardiovascular 
risk as a continuous measure (-0.4 (-1.2 to 0.3)). The intervention was associated with improvements 
in diet, physical activity, medication adherence, and satisfaction with access to care, treatment 
5 
 
received and care co-ordination. There was one serious related adverse event: a participant 
hospitalised with low BP. 
CONCLUSIONS 
This evidence based telehealth approach was associated with small clinical benefits for a minority of 
people with high cardiovascular risk, and there was no overall improvement in average risk. 
However, the Healthlines Service was associated with improvements in some risk behaviours, and in 
perceptions of support and access to care.   
TRIAL REGISTRATION 
Current Controlled Trials (ISRCTN 27508731). 
 
 
(403 words) 
 
 
 
Introduction 
The growing prevalence of long-term conditions means that new and more efficient approaches to 
health care delivery are needed which support people to manage their own care, with less reliance 
on consultations with expensively trained health care professionals. Effective self-management, as 
part of a shift in the management of long-term conditions, can help improve health outcomes and 
reduce costs.1 2 Many countries are exploring a greater use of technologies such as the internet, 
remote monitoring, and telephone support as a way of expanding provision and increasing access to 
care for a large number of people at relatively low cost. In the UK, current policy envisages these 
‘telehealth’ approaches as having potential to transform the delivery of health care in order to make 
the NHS sustainable for the future.3 In the United States, the Veterans Health Administration has 
enrolled more than 50,000 people in a home telehealth program, 4 5 and in Europe the Renewing 
Health Consortium is evaluating telehealth programmes in nine countries.6 
There is a burgeoning volume of literature on the effectiveness of specific telehealth interventions, 
with promising effects for some applications. However, recent reviews have highlighted that much 
of the evidence is of poor quality, results are inconsistent, there is a lack of theoretical underpinning 
which makes it difficult to interpret the mixed results, and there is some evidence of publication bias 
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in favour of positive results.7-10 Furthermore, focusing on specific applications or technologies in 
isolation is of limited value since they need to be considered in the context of their implementation 
within the health care system. In practice, large scale health care programmes based on telehealth 
involve the combined use of technologies, for example online programs and/or remote monitoring 
with telephone support from advisors following computerised algorithms. In the recent 5 year 
strategic plan for the NHS, it is argued that evaluation is needed of ‘combinatorial innovation’, in 
which a range to technologies are provided in combination with new ways of working.11 12 There are 
very few rigorous pragmatic studies of real world implementation of this approach.8 Furthermore, a 
key aspect of the argument for telehealth is increased efficiency, but there are few studies 
incorporating economic analyses and the limited evidence available suggests that many telehealth 
interventions are not cost-effective.13  
We conducted a research programme to develop a conceptual model for the effective use of 
telehealth in long-term conditions, based on literature reviews,14 15 qualitative research16 and 
surveys of patient views.17 Designated the Telehealth in Chronic Disease (TECH) model, this builds on 
existing approaches such as the Chronic Care Model by creating a framework for improving chronic 
disease management via telehealth.18 We used this model to design the Healthlines Service for the 
management of long-term conditions, based on the combined use of internet based health 
applications which had evidence of effectiveness supported by non-clinically qualified staff working 
using tailored computerised algorithms.19  
We evaluated the Healthlines Service through linked pragmatic multi-centre randomised controlled 
trials with nested process and economic evaluations in two exemplar conditions: depression or 
raised cardiovascular risk. This paper reports the findings with regard to patients with raised 
cardiovascular risk. Although hypertension, obesity and hyperlipidaemia are often considered as 
long-term conditions, it is more appropriate to consider them as risk factors, with their combined 
effect determining overall cardiovascular risk.20 This was considered an appropriate exemplar 
because of the very high number of people affected (10% of adults aged 35-74 in England and Wales 
have 10 year cardiovascular risk ≥20%),21 which has serious health consequences due to heart 
attacks, strokes, kidney disease and other problems. Cardiovascular disease causes 28% of deaths in 
England, accounts for 10% of all hospital admissions, and involves an annual expenditure in England 
of almost £7 billion.22 A low cost intervention which could be made widely available to large 
numbers of individuals could have a beneficial impact at a population level even if the effect for an 
individual was small.  
There is existing evidence for the effectiveness of specific relevant technological approaches, such as 
home BP monitoring,23 mobile phone applications to support smoking cessation,24 and online 
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interventions for weight loss.25 This provided a good basis for the hypothesis that combining these 
‘active ingredients’ and implementing them within a new telehealth model of care would be 
effective and cost-effective. Furthermore, the introduction in 2008 of the NHS ‘Health Check’ 
programme was likely to identify a large number of people with high cardiovascular risk, and there 
was a need to explore ways to expand provision of care to manage them once they had been 
identified.26  
Our hypothesis was that the Healthlines Service for patients with high cardiovascular risk would be 
more clinically and cost-effective than usual care, while also improving participant’s quality of life, 
risk behaviours, and experience of care.  
Methods 
Design 
This was a pragmatic, multi-centre, randomised controlled trial comparing the Healthlines Service in 
addition to usual care versus usual care alone in adults with a high risk of cardiovascular disease. The 
study was registered prior to recruitment of the first participant and the study protocol has been 
published.19 There were no important changes to the methods after the trial commenced, apart 
from the addition of a nested sub-study of different forms of patient invitation information to assess 
the impact on participant recruitment rates. This did not alter the design or outcomes for the main 
trial; results of this sub-study are published elsewhere. 27 
Participants 
Patients eligible for the trial were aged between 40 and 74 years of age, had a risk of a 
cardiovascular event in the next 10 years of ≥20% calculated using the QRISK2 score,21 and had one 
or more of the following modifiable risk factors (systolic blood pressure (BP) ≥140, body mass index 
(BMI) ≥30, and/or being a current smoker). Participants required access to a telephone, the internet, 
and an email address. We excluded people who had a previous cardiovascular event; were pregnant 
or planning pregnancy; had a serious mental health problem, dementia, severe learning disability, or 
substance dependency; were receiving palliative care; or were unable to communicate verbally in 
English.  
Participants were recruited from 42 general practices covering populations with a range of socio-
demographic characteristics in and around Bristol, Sheffield and Southampton, England. We used 
patients’ medical records to identify individuals who had at least one modifiable risk factor and 
estimated 10 year cardiovascular risk of ≥18% (we were over-inclusive at the initial screening stage 
because QRISK2 scores based on historical records may not reflect current risk and we wanted to 
invite potentially eligible individuals to have an updated risk assessment). A random sample of these 
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potentially eligible patients in each practice was sent postal information about the study, after GPs 
screened the list for patients with known exclusion criteria. We sent information to between 250 
and 285 patients in each practice, altering the sampling fraction over time in order to achieve our 
recruitment targets. Patients who expressed an interest in the study were telephoned by a 
researcher to conduct initial eligibility screening and then invited for an assessment of 
cardiovascular risk status by a practice nurse at their participating general practice. The nurse 
measured the patients’ BP, weight and height, smoking status and total cholesterol to high-density 
lipoprotein ratio, and collected all other relevant information needed to calculate the patient’s 
QRISK2 score (see Appendix 1). Patients who had a QRISK2 score ≥20% and had one or more of the 
specified modifiable risk factors completed a baseline questionnaire and consent form, either online 
or by post. 
Intervention and control  
Participants in the control group could continue to receive all care normally provided by the NHS, 
but they did not have any contact with the Healthlines Service. Usual care involved management of 
cardiovascular risk factors by primary care clinicians, including in some cases referral to community 
services for advice about smoking cessation and weight management.  
Participants in the intervention arm received support from the Healthlines Service in addition to 
usual NHS care as described above. The Healthlines Service is a multi-faceted intervention, 
incorporating a range of strategies to address the various components of the TECH model,18 as 
shown in Box 1. The intervention is based around regular telephone calls from a health advisor, 
supported by patient-specific tailored algorithms and standardised scripts generated through a 
computerised behavioural management programme. This programme was originally developed and 
successfully evaluated in the USA by Bosworth et al and includes a series of modules on subjects 
such as medication adherence, diet and smoking cessation.28 29 The standardised scripts generated 
by the software were based on recognised behaviour change principles, such as stimulus control, 
problem solving, cognitive restructuring, and goal setting.30 We modified the programme to reflect 
English management guidelines and referral options, wrote additional modules with new content 
and adapted the language to suit an English population.   
Health advisors telephoned each participant for an initial assessment of their health needs and to 
agree their specific goals. Following the initial call, the advisors telephoned each participant 
approximately every month for one year. The software was interactive and provided different 
computerised scripts so that the content of each call was tailored to meet each participant’s 
individual needs and goals. The software provided health advisors with links to relevant and quality 
assured online resources and applications to support self-management (for example, to help with 
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losing weight or stopping smoking) and the advisors sent these links to participants by email or by 
post.  Each participant was telephoned by the same advisor on each occasion when possible in order 
to avoid an anonymous ‘call-centre’ approach, since our earlier qualitative research had identified a 
relationship with the advisor as an important factor in engaging prospective participants.15 The 
Healthlines Service was designed to improve access to care and was available until 8pm on weekdays 
and 2pm on Saturdays. 
Participants were also provided with access to a Healthlines web portal where they could obtain 
further information about cardiovascular disease, access other online resources, request a call-back 
from Healthlines staff, see copies of letters to their GP and use a BP self-monitoring system. 
Participants with a baseline systolic BP ≥ 140 were offered an Omron M3 validated home BP monitor 
by their practice nurse, requested to take their BP twice daily for the first week and weekly 
thereafter, and to upload their readings to the Healthlines portal. The portal calculated average 
readings over the previous six days initially and then over the previous six weeks thereafter. Using 
these readings, the participant was automatically advised by the portal whether their BP was within 
their target, when to take their BP again and what to do if their BP was too high or too low. Target 
BP was based on UK guidelines,31 although an individual’s target could be modified by their GP. 
Average BP readings were reviewed by health advisors at each telephone call, and participants with 
above target readings were asked to see their GP to review their treatment. Advisors sent an email 
to the GP, attaching details of the patient’s recent BP readings and a summary of NICE guidelines 
about recommended steps for intensifying treatment.  
The Healthlines advisors were not clinically qualified but had experience working as health advisors 
for NHS Direct and had a further three weeks of training in health coaching, motivational 
interviewing, treatment options (including medication) for hypertension, smoking and obesity, and 
use of the Healthlines computerised management programme.  
The Healthlines Service was originally hosted by NHS Direct, which provided a range of telehealth 
services through a network of call centres and a nationally recognised website. When NHS Direct 
closed in March 2014 delivery of the intervention was paused for two months while the staff and 
computer systems were transferred to a new provider (Solent NHS Trust). Although the Healthlines 
Service resumed unaltered after this hiatus, about two-thirds of participants experienced some 
disruption and some participants could not receive the full number of telephone calls during their 12 
month follow-up period.  
Outcomes 
The primary outcome was the proportion of participants responding positively to treatment, defined 
as maintaining or reducing their 10 year cardiovascular risk 12 months after randomisation, 
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estimated using the QRISK2 score. Since cardiovascular risk increases with age, maintaining or 
reducing risk over 12 months requires an improvement in at least one modifiable risk factor. We 
treated QRISK2 score (continuous) as a secondary outcome. The estimate of risk was based on data 
collected at an assessment by a nurse or health care assistant at the participant’s general practice at 
6 and 12 months after recruitment using the same procedures as used at baseline (see Appendix 1). 
Follow-up QRISK2 scores were calculated by updating age and values for modifiable risk factors only. 
Other variables such as diagnoses of atrial fibrillation or diabetes were not altered to avoid bias due 
to the greater attention paid to participants in the intervention arm.  
Cardiovascular risk is a composite outcome, and the individual risk factors of BP, weight (and body 
mass index), smoking and cholesterol were important secondary outcomes. Other secondary 
outcomes were quality of life; exercise; diet; satisfaction with treatment received and with amount 
of support received; perceived access to care; self-management skills and self-efficacy; medication 
adherence; health literacy; use of telehealth and perceptions of care co-ordination. The specific 
measurement instruments used are referenced in Table 6. Secondary outcome measures were 
collected through patient questionnaires, completed online or by post, at baseline and 6 and 12 
months after randomisation. Data about prescriptions and primary care consultations were obtained 
from general practice records while details of use of the intervention were obtained from 
Healthlines Service records. Potential serious adverse events were identified through reports from 
participants or health professionals, further enquiry about hospital admissions reported in outcome 
questionnaires, or admissions, deaths or other potential serious adverse events identified through 
review of primary care notes at the end of the trial. All such events were logged with a description of 
the event and an assessment of expectedness, relatedness and seriousness and reported to the trial 
monitoring committee, sponsor and ethics committee as appropriate. 
Sample size 
The sample size was chosen pragmatically, taking into account the size of effect that would be likely 
to influence practice and which might be feasible to detect in a trial of reasonable size. Based on a 
previous study we assumed that 35% of participants in the control arm would maintain or reduce 
their cardiovascular risk over 12 months.38 Including 240 participants per trial arm for analysis would 
provide 80% power (5% alpha) and 90% power (1% alpha) to detect differences of 13 and 18 
percentage points, respectively.  Assuming 20% attrition, we therefore aimed to recruit 600 
participants, 300 in each trial arm.  
Randomisation and masking 
Participants providing consent were individually randomly allocated in 1:1 ratio to the intervention 
or usual care group. Allocation was made using a web randomisation system hosted by the Bristol 
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Randomised Controlled Trials Collaboration, and automated to ensure concealment. Randomisation 
was stratified by location of recruitment (Bristol, Sheffield, or Southampton) and minimised by 
general practice and baseline QRISK2 score. Participants were notified of their allocation by the 
researchers by email. Participants were not masked to treatment allocation. Data for the QRISK2 
score were collected by practice nurses or health care assistants, who may have been aware of 
treatment allocation at follow-up, but the variables of relevance on smoking (validated using a 
carbon monoxide monitor), BP and cholesterol were all based on objective quantitative data. All 
other outcome data were collected by participant self-report or electronic download from medical 
records and were entered and analysed blinded to treatment allocation.  
Statistical analysis 
Analysis was conducted according to CONSORT guidelines, following an analysis plan agreed in 
advance with the independent Trial Steering Committee and Data Monitoring Committee. 
Descriptive statistics were used to compare baseline characteristics of trial participants by allocated 
arm. The primary analysis of response to treatment after 12 months was conducted using a mixed 
effects logistic regression model adjusted for site, baseline QRISK2 score, and general practice (as a 
random effect). Participants were analysed according to allocated arm. We conducted sensitivity 
analyses of the primary outcome using: the assumption that all participants were exactly one year 
older at 12 months follow-up; simple imputation of missing outcome data that assumed no 
treatment response; multiple imputation of missing data; exclusion of GP practice as a random 
effect; and adjustment by time between randomisation and follow-up. By fitting interaction terms 
between trial arm and subgroup variables, we investigated whether any effect of the Healthlines 
intervention on the primary outcome differed according to subgroups defined by sex, age, baseline 
QRISK2 score, and presence or absence of each of the modifiable risk factors (hypertension, obesity, 
smoking) at baseline.  
In secondary analysis of the primary outcome, we estimated the complier-average causal effect 
(CACE) of the Healthlines intervention when received as intended. We described compliance as little 
or none (two or fewer telephone calls), partial (three to 11 calls) or full (12 or 13 calls). We 
estimated the CACE at 12 months using principal stratification in two ways, classifying partial 
compliers as either non-compliers or full compliers respectively.39  
Secondary outcomes were analysed in a similar manner to the primary outcome. Between-group 
effects were estimated using linear, logistic or binomial mixed effects regression models, adjusted 
for stratification and minimisation variables and value of the outcome at baseline. Participants were 
analysed as randomised without imputation of missing data. In order to reduce the number of 
statistical comparisons, we estimated between-group differences for secondary outcomes (other 
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than cardiovascular risk factors) only at the final 12 month follow-up time-point. We described 
serious adverse events by study arm.  
We assessed the cost-effectiveness of the Healthlines intervention from an NHS perspective at 12 
months from randomisation. Cost-effectiveness was not listed as a secondary outcome in the trial 
registry because we viewed it as an approach to analysis rather than as an outcome; however 
assessment of cost-effectiveness was specified a priori as an aim in the registry and described in the 
published protocol.  The methods and results of the economic evaluation will be described in detail 
elsewhere. In brief, health system costs were compared with incremental quality-adjusted life years 
(QALYs), measured using the EQ-5D-5L generic quality of life questionnaire32 at baseline and six and 
12 months post-randomisation, in order to produce an estimate of net monetary benefit. We also 
developed a cohort simulation model in order to estimate the cost-effectiveness of the intervention 
over the estimated remaining lifetime of trial participants.  
All analyses were conducted using Stata version 13 MP2. The trial was registered prospectively with 
Current Controlled Trials (ISRCTN 27508731).  
Patient involvement 
There was strong and valuable patient and public involvement throughout the Healthlines research 
programme. Two service user groups (Mental Health Research Network and NHS Direct user group) 
provided feedback on the initial questionnaire about patients’ preferences and needs in relation to 
telehealth which helped to inform the intervention design.17 Two representatives of these groups 
became members of the Management Group for the five year research programme. They 
contributed to the design of the patient survey,17  participated in a workshop to develop the TECH 
model which underlies the intervention,18 and became members of the Trial Steering Committee for 
the randomised trial.19  They commented on the acceptability of the intervention to potential 
participants and obtained feedback from their user groups on the outcome measures. At the end of 
the trial they contributed to a workshop of key stakeholders that was held to discuss interpretation 
and dissemination of the findings. They also provided useful feedback on the final report of the 
programme, and in particular the lay summary. We have thanked all participants for their 
involvement and given them details of the website where all published results will be made 
publically available (http://www.bristol.ac.uk/healthlines/).  
Results 
Participants were recruited between 3 December 2012 and 23 July 2013.  Of 7,582 people sent 
information about the study, 1205 (16%) individuals expressed interest and were assessed. Of these, 
641 were eligible and randomly allocated to the Healthlines intervention (n=325) or usual care arms 
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(n=316) (Figure 1). 597 (93%) of participants provided follow-up data after 6 months follow-up and 
586 (91%) after 12 months follow-up (the primary outcome).     
Characteristics of participants in the trial are shown in Table 1. Overall, the participants were at high 
risk of a cardiovascular event (mean 10 year risk 31%) due to combinations of modifiable and non-
modifiable risk factors. Participants were predominantly white men aged over 60, and at baseline 
356 (56%) had obesity (BMI>=30), 450 (70%) had a BP≥140 and 528 (18%) were currently smoking. 
The two trial arms were well balanced except that there were fewer smokers and more participants 
with diabetes in the intervention arm. These factors both contribute to the baseline QRISK2 score, 
which was included as a covariate in all analyses, so we did not conduct additional statistical 
adjustment for these imbalances. 
Primary outcome 
After 12 months, a slightly higher proportion of participants in the intervention arm had improved or 
maintained their cardiovascular risk compared with the usual care arm (50.2% versus 42.6% 
respectively; number to treat 13), although this apparent difference had wide confidence intervals 
and could be due to chance (adjusted odds ratio 1.3 [95% confidence interval 1.0 to 1.9]; p=0.079). 
This conclusion was largely unchanged in our sensitivity analyses (Table 2). There was no evidence 
that the intervention was differentially effective for any of the pre-specified sub-groups defined by 
baseline characteristics, although the study was not powered to detect these interaction effects 
(Table 3).  
Secondary outcomes 
There was no evidence of any between group difference in the proportion of participants who 
improved or maintained their cardiovascular risk after 6 months follow-up (Table 2). There was also 
no evidence of difference between groups in QRISK2 score when treated as a continuous measure 
(Table 4). However, the intervention was associated with improvements in some of the individual 
modifiable risk factors which contribute to cardiovascular risk, including reductions in systolic and 
diastolic BP and in weight and body mass index after 12 months follow up (Table 4). The intervention 
did not lead to improvements in cholesterol levels (Table 4) or rates of smoking (Table 5). 
Table 6 shows that the intervention was associated with improvements in several of the secondary 
outcomes. Participants in the intervention arm reported that they improved their diets and 
increased their level of exercise. They were more likely to adhere to their treatment with statins and 
with anti-hypertensive medication. Intervention arm participants reported improved access to care, 
and expressed greater satisfaction with the amount of support they received and their overall 
treatment. They also reported that their care was better organised and co-ordinated.  For ease of 
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presentation, Table 6 only shows data on secondary outcomes after 12 months follow-up. Findings 
after six months are available from the authors. 
After 12 months, the incremental cost-effectiveness ratio was estimated to be £10,859 in 2012/13 
prices (incremental cost £138 [£66 to £211]; incremental QALY gain 0.012 [-0.001 to 0.026]). The net 
monetary benefit at a cost-effectiveness threshold of £20,000 was estimated to be £116 (95% CI: -
£58 to £291). The intervention was likely to be cost-effective at this threshold after 12 months with a 
probability of 0.77.  The cohort simulation study showed that the lifetime cost-effectiveness of the 
intervention increased the greater the duration of effect of the intervention on cardiovascular 
disease risk beyond the follow-up period of the trial. Further details will be published elsewhere. 
Engagement with the intervention 
Participants in the intervention arm received a median of 10 (IQR 8 to 12) encounters with the 
Healthlines cardiovascular service out of a possible maximum of 13 encounters. The mean duration 
of each encounter was 18 (SD 9.5) minutes. Using a complier-average causal effect (CACE) analysis 
we explored whether the number of encounters received in the intervention arm was associated 
with the primary outcome. The results suggest an increase in effect of the intervention amongst 
participants who received all or most of the planned number of encounters (Table 7).  
Participants in the intervention arm logged in to the Healthlines website on a median of 14 (IQR 3 to 
47) occasions, more than once a month. 296 (91%) of participants were given a BP monitor, of which 
200 entered at least one reading, uploading a median of 70 (IQR 48 to 102) BP readings. 
Healthlines advisors sent a median of 5 (IQR 2 to 9) letters by email to participants’ GPs. Of these, 
138/310 of the participants’ GPs were sent letters advising commencement or review of BP 
medication, 32 (10%) were asked to consider starting statin therapy, 7 (2%) were asked to prescribe 
orlistat for obesity and 3 (1%) were asked to prescribe medication to aid smoking cessation. 
However, based on data from the medical records, there were no differences between the 
intervention and control group in the number of changes in medication (starting new treatments or 
changing dose) for hypertension or lipid-lowering drugs, with a median of zero (IQR 0 to 1) changes 
for both types of treatment.  Similarly, there was no evidence of difference between the arms in the 
proportion of participants who reported taking statins or medication for hypertension, the 
proportion who had a change in treatment prescribed, or the types of medication prescribed (Table 
8). These data were not specified as outcomes but are presented here to explore the mechanism of 
effect of the intervention.  
Over the 12 month period, there was no evidence of difference between the intervention and 
control arms in the number of times participants consulted in primary care (mean 11.28 (SD 8.8, 
n=313) and 11.42 (SD = 7.9 n=325) respectively, adjusted incidence ratio 0.99 (0.89 to 1.09, p=0.77)).  
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Patient safety 
Over the course of the trial there were 76 adverse events reported by participants, 38 in each trial 
arm. There were 24 serious and unexpected events in the usual care arm and 22 in the intervention 
arm (Appendix 2). Only one serious event in the intervention arm was likely to be related: a 
participant was hospitalised with low BP which could have been due to not reducing his 
antihypertensive medication after he had lost weight.   
Discussion 
Principal findings 
This study suggests a modest benefit from the Healthlines Service in terms of the proportion of 
individuals reducing or maintaining their cardiovascular disease risk over 12 months. Despite the 
large sample size, the estimate of effect has wide confidence intervals and could be consistent with 
no effect or a 90% increase in the odds of reducing/maintaining risk. The results for the primary 
outcome were not statistically significant in either the complete case analysis or after multiple 
imputation of missing data. Furthermore, there was no evidence of difference between the trial 
arms in average risk, treating QRISK2 as a continuous measure (a secondary outcome). 
Cardiovascular risk is a composite measure, based on several underlying risk factors. The Healthlines 
intervention was associated with small but meaningful improvements in several of these factors, 
including reductions in BP and weight, but not in cholesterol or smoking. It was also associated with 
improvements in self-management behaviours such as diet and physical activity, better adherence 
to medication, and greater participant satisfaction with support, access to care and treatment 
received. It is important to note that these improvements in self-management behaviours would 
reduce cardiovascular risk beyond the benefit captured in the QRISK2 score and are also likely to 
reduce risk for many other common and serious diseases, so our focus on cardiovascular risk 
measured using QRISK2 is likely to be conservative in terms of estimating overall benefit.  
The intervention was not successful at promoting optimisation of drug treatment in line with current 
guidelines, which was a key intended mechanism for reducing BP and cholesterol levels. This is 
consistent with previous research highlighting the problem of clinical inertia – that treatment is not 
necessarily intensified in people who fail to reach treatment targets even when regular monitoring 
shows inadequate control.40 Although the observed reduction in cardiovascular risk was small (and 
could be due to chance), the likely reduction in cardiovascular events in the longer term means that 
the Healthlines Service was likely to be cost-effective.  
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Strengths and limitations 
This appears to be the largest pragmatic trial so far conducted of a telehealth intervention to reduce 
cardiovascular risk. It is a complex intervention combining a range of telehealth approaches, and has 
a strong theoretical foundation based on the underlying TECH conceptual model.18 The large sample 
size and high level of participant retention enhance internal validity, while the multi-centre 
recruitment and broad inclusion criteria enhance external validity.  
The Healthlines intervention incorporates the use of a number of telehealth approaches which have 
reasonable evidence of effectiveness, such as home BP monitoring, and we sought to implement 
them on a wide scale. Most research studies of telehealth interventions relate to specific 
technological innovations and can be characterised as efficacy trials, in that they demonstrate the 
effect of a well-defined intervention in individuals with tightly defined inclusion and exclusion 
criteria, and who are motivated to use the particular application. These studies may lead to 
estimates of effect which are exaggerated when compared with the effects observed when the 
application is implemented more widely. By contrast this trial was pragmatic, testing an intervention 
as delivered by a mainstream NHS provider in a way that could be rolled out quickly on a wide scale.  
There are several limitations. Firstly, only 16% of those sent information about the study expressed 
interest in it. This response rate is not unusual in primary care based trials in which people who may 
not have an expressed health need are invited to take part in research, indeed the response rate in 
this trial was higher than in several other influential trials of related interventions.41-43 However, if 
non-respondents differ from respondents because of disinterest in research this could reduce the 
generalisability of trial findings. Based on information from 2741 people who gave a reason for non-
participation the most common reasons were related to technology rather than research: 1491 
(54%) had no internet access and 1225 (45%) did not feel confident using computers (people could 
provide more than one reason).44 Many people 1135 (41%) did not feel they needed additional 
support with health issues. It is important to note that less than half of those invited for an NHS 
Health Check attend, and not everyone who smokes or is over-weight is motivated to change.  We 
also recognise that telehealth interventions are not necessarily of interest to everyone and take-up 
in routine service use may be low. However, health care is likely to be increasingly personalised, with 
different forms of care being chosen by different groups in the population.  Telehealth interventions 
may be useful for a minority of potential participants if (as in the case of raised cardiovascular risk) 
the total number of people at risk is large.  
Second, the closure of NHS Direct towards the end of the trial meant that delivery of the 
intervention was disrupted and many participants received less than the full course of intervention 
encounters. However the fact that we were able to move the service quickly to another provider 
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demonstrates the transferability of the approach. Third, we analysed a large number of secondary 
outcomes in order to capture the range of potential effects from this complex intervention, but this 
raises the possibility of some apparent differences being due to chance because of multiple testing. 
Fourth, the sample size was chosen pragmatically and assumed that 35% of control arm participants 
would maintain or reduce the cardiovascular risk over 12 months. In the trial, a higher than 
anticipated proportion of those in the control group achieved this, perhaps because of the impact of 
the NHS Health Checks programme.26 This reduced the power of the study to detect differences 
between the intervention and control groups, but this will have been mitigated to some extent by 
the fact that we recruited and successfully followed up more patients than anticipated. Fifth, the 
study was limited to patients under 75 years of age (because this is the age range in which QRISK2 
has been validated and is also the age-group targeted by NHS Health Checks), but this intervention 
could potentially also help older people. The study also excluded people without access to the 
internet, however the proportion of the population with access is increasing rapidly. 
Finally, the use of cardiovascular risk as a composite outcome has limitations because the QRISK2 
score is strongly dominated by non-modifiable factors such as age and sex. We chose to analyse the 
QRISK2 as a binary measure of ‘response to treatment’ for the primary outcome because this 
approach is sensitive to changes in modifiable risk factors. The number of patients ‘needed to treat’ 
to gain benefit from the intervention was 13. However, because only a minority of participants 
benefited, there was no significant change in QRISK2 averaged across all participants when analysed 
as a continuous variable (a secondary outcome). Nevertheless the small changes in modifiable risk 
factors observed in this trial are likely to be associated with meaningful benefits. Based on the 
systematic review by Law et al,45 the reductions in blood pressure observed in this trial would lead to 
a 23% reduction in the relative risk of stroke and a 15% reduction in the relative risk of a heart 
attack. The combined effect (along with the reduction in weight) suggests that these small changes 
in modifiable risk factors are likely to be worthwhile, particularly at a population level when applied 
to the very large number of people with high risk of cardiovascular disease. 
Comparison with other studies 
This was a trial of the implementation of the combined use of a range of telehealth interventions to 
address cardiovascular risk factors. The results are broadly consistent with earlier trials which have 
studied different components of the intervention in isolation to reduce individual risk factors. A 
systematic review of trials of BP self-monitoring showed that this was associated with small 
reductions in both systolic and diastolic BP of a similar size to those achieved in the Healthlines CVD 
risk trial.23 A Cochrane review found that computer based interactive interventions for weight loss 
were associated with a mean weight loss of 1.5kg (95% CI 0.9 to 2.1kg) compared with no or minimal 
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intervention, an effect which is also consistent with our findings.25 Systematic reviews on internet 
based telehealth interventions for smoking cessation show mixed effects, although mobile phone 
interventions based interventions are effective and telephone ‘quitlines’ can improve cessation rates 
in those people who pro-actively contact them.24 46 47 It is important to note that the above reviews 
were all based on individuals who had the risk factor of interest and many trials only included 
individuals who were motivated to change the specific risk factor. In the Healthlines CVD risk trial 
only a proportion of participants had raised BP, obesity or were smokers at baseline, and they were 
not necessarily motivated to change the main factor contributing to their risk, so effects are likely to 
be smaller than in studies on specific risk factors.  
The Healthlines intervention tested in this trial had a similar impact on reducing BP as the earlier 
trials by Bosworth et al which used a similar behavioural management system (but provided by 
nurses rather than lay staff and without incorporating the use of internet resources).28 29 However, it 
had less impact than two trials from the USA which involved BP self-management with pharmacist 
management of medication by phone or over the internet.41 42 The involvement of pharmacists to 
directly alter medication without the intermediate step of sending advice to primary care physicians 
may be associated with more effective optimisation of treatment, but could be problematic in a 
routine primary care context when patients often have comorbidities and other factors need to be 
considered in treatment decisions.  
Two systematic reviews of telehealth interventions to reduce overall cardiovascular risk have 
recently been published.14 48 Several studies demonstrated small improvements in BP and weight, 
findings with regard to cholesterol were equivocal, and there was no evidence of increased rates of 
smoking cessation. Our results are consistent with these findings but provide much stronger 
evidence from a large, rigorous and pragmatic trial. 
Implications for clinicians and for policy 
The development of the Healthlines Service reflected a conceptual framework which was based on 
promoting self-management, improving medication adherence and optimisation of drug treatment, 
improving co-ordination of care and the active engagement of patients and primary care clinicians.18  
This randomised controlled trial shows modest but cost effective benefit in cardiovascular risk 
reduction. Delineating how components of a multi-faceted intervention work, alone or in 
combination; their effect on physician practice in terms of optimisation/intensification of medicines 
and their effect on behaviour modification by patients is complex. What is clear is that patients who 
engaged with the intervention appear to gain the most in terms of cardiovascular risk but some 
components of the intervention, particularly optimisation/intensification of drugs, were ineffective.  
In order to improve the effectiveness of the intervention it will be important to target it at those 
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who are motivated to change their risk behaviours, and to improve communication with primary 
care prescribers with regard to drug treatment recommendations.  
There has been considerable optimism about the potential of telehealth approaches to improve the 
accessibility, convenience and efficiency of health care.  This study adds to the growing evidence 
base which suggests that healthcare delivery systems based on telehealth may be associated with 
some benefits but these should not be assumed. However, this study has demonstrated the 
feasibility of delivering an intervention on a wide scale at relatively low cost, and using non-clinically 
trained health advisors supported by computerised algorithms. This increases the capacity of the 
health care system to provide an intervention to large numbers of people. Further development of 
this type of intervention is justified to increase the effectiveness of the Healthlines approach.   
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Figure 1. Flow of participants through trial comparing Healthlines cardiovascular disease 
intervention and usual care 
 
 
 
(See PDF file Figure 1)  
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Box 1. Components of the Healthlines CVD risk intervention, reflecting the TECH conceptual mode. 
Examples of strategies are show in italics 
• Computerised behaviour management program 
- Providing interactive scripts used by health advisors 
- Identifying patient goals and tailoring intervention.  
- Modules include: 
o Knowledge about cardiovascular risk and healthy lifestyles 
o Medication and side effects review 
o Blood pressure medication optimisation 
o Home BP monitoring 
o Statin medication review 
o Support for medication adherence 
o Smoking and nicotine replacement therapy 
o Healthy eating 
o Weight loss and Orlistat 
o Alcohol use 
o Exercise 
• Motivational interviewing 
- Health advisors all trained in motivational interviewing 
• Self-monitoring and feedback 
- BP online self-monitoring programme with automated feedback 
• Treatment optimisation and intensification 
- Health advisors monitor treatment response. In patients with inadequate control, recent readings 
and a request to intensify treatment, along with reminders of treatment guidelines emailed to 
clinicians and copied to patients  
• Addressing medication adherence 
- Monthly review of medication adherence; algorithmic scripts based on evidence based strategies to 
promote adherence 
• Improving care co-ordination 
- sharing all information sent to clinicians with patients 
• Supporting primary care 
- all aspects of the intervention designed to support rather than duplicate primary care 
• Strategies to promote patient engagement 
- through continuity of care with the same advisor; providing technical support with getting online  
• Strategies to promote primary care clinician engagement 
- emphasising evidence based nature of intervention components and how it can support their work 
in primary care 
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Table 1 Baseline characteristics of participants allocated to usual care or the Healthlines 
intervention. Figures are numbers (percentages) unless otherwise stated. 
 Usual care   (n = 316) Intervention     (n = 325) 
Demographic data  n/N  n/N 
Mean age at cardiovascular assessment (SD) 67.3 (4.7) 316 67.5 (4.9) 325 
Number female (%) 21% 66/316 18% 60/325 
Number White (%) 99% 313/316 99% 321/325 
Current employment situation     
Number in full-time employment (%) 13% 39/311 17% 54/316 
Number in part-time employment (%) 14% 43/311 9% 29/316 
Number unemployed (%) 1% 4/311 1% 2/316 
Number unable to work due to long-term illness/disability (%) 2% 7/311 1% 3/316 
Number unable to work due to carer responsibilities (%) 1% 3/311 1% 2/316 
Number fully retired from work (%) 63% 196/311 66% 210/316 
Number looking after the home (%) 1% 3/311 1% 4/316 
Number doing something else (%) 5% 16/311 4% 12/316 
Occupation (most recent or current)     
Number in administrative or secretarial occupations (%) 11% 31/294 10% 29/294 
Number in associate professional or technical occupations (%) 15% 45/294 12% 35/294 
Number in elementary occupations (%) 10% 28/294 5% 16/294 
Number of managers or senior officials (%) 19% 55/294 22% 65/294 
Number in personal services (%) 2% 5/294 3% 9/294 
Number of process, plant and machine operatives (%) 5% 15/294 6% 17/294 
Number of professionals (%) 19% 57/294 22% 64/294 
Number in sales and customer services (%) 4% 11/294 4% 13/294 
Number in skilled trades (%) 16% 47/294 16% 46/294 
Highest education qualification achieved     
Number with degree or higher degree (%) 21% 65/307 23% 72/318 
Number with A levels or equivalent (%)  19% 58/307 17% 53/318 
Number with GCSEs/O levels or equivalent (%)  45% 137/307 43% 136/318 
Number with no qualifications (%) 15% 47/307 18% 57/318 
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 Usual care   (n = 316) Intervention     (n = 325) 
Accommodation     
Own accommodation or buying with mortgage (%) 84% 264/315 87% 281/323 
Part-rent or rent accommodation (%)  15% 46/315 12% 40/323 
Live rent free (%) 2% 5/315 1% 2/323 
Mean Index of Multiple Deprivation (SD) 16.7 (12.6) 316 15.5 (11.3) 325 
Clinical data     
Mean QRISK2 score (SD) 30.8 (9.5) 316 31.1 (10.2) 325 
Mean systolic blood pressure (SD) 148.1 
(17.6) 
316 147.6 
(16.2) 
325 
Mean diastolic blood pressure (SD) 80.0 (10.4) 316 81.2 (9.6) 325 
Mean weight (SD) 91.9 (18.9) 316 93.2 (17.3) 325 
Mean body mass index (SD) 30.9 (5.7) 316 31.2 (5.4) 325 
Mean total cholesterol (SD) 4.9 (1.2) 315 4.9 (1.2) 324 
Mean total cholesterol/HDL ratio (SD) 4.2 (1.4) 315 4.2 (1.5) 323 
Number of non-smokers (%)  33% 103/316 35% 114/325 
Number of ex-smokers (%) 47% 148/316 50% 163/325 
Number of light smokers (%) 9% 30/316 8% 25/325 
Number of moderate smokers (%) 5% 17/316 5% 16/325 
Number of heavy smokers (%) 6% 18/316 2% 7/325 
Number taking anti-hypertensives (%) 61% 193/316 64% 209/325 
Number taking lipid-lowering medication (%) 49% 153/312 49% 158/322 
Number with diabetes (%) 20% 62/316 24% 77/325 
Number with chronic kidney disease (%) 11% 34/316 6% 20/325 
Number with atrial fibrillation (%) 6% 20/316 7% 23/325 
Number with rheumatoid arthritis (%) 3% 8/316 2% 6/325 
SD = Standard deviation; CVD = cardiovascular disease; GCSE = General Certificate of Secondary Education; 
HDL = high density lipoprotein cholesterol. 
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Table 2 Improving or maintaining cardiovascular risk as a binary outcome 
 Usual care 
N = 291 (12 
months); 296 (6 
months); 316 
for imputed 
data  
% (n/total) 
 
Intervention 
N = 295 (12 
months); 301 (6 
months); 325 
for imputed 
data 
% (n/total) 
Adjusted odds ratio 
(95% confidence 
interval) 
P-value 
Primary analysis     
Improved/maintained 
QRISK2 after 12 months 
43% (124/291) 50% (148/295) 1.3 (1.0 to 1.9) 0.079 
Secondary analysis     
Improved/maintained 
QRISK2 after 6 months 
46% (137/296) 48% (145/301) 1.1 (0.8 to 1.5) 0.654 
Sensitivity analyses of  improved/maintained QRISK2 after 12 
months 
  
Assuming all participants 
were one year older 
45% (130/291) 52% (153/295) 1.3 (1.0 to 1.9) 0.096 
 
Simple imputation, 
assuming missing binary 
outcome is non-response 
40% (124/316) 46% (148/325) 1.3 (0.9 to 1.8) 0.109 
 
Multiple imputation 44% (139/316) 50% (163/325) 1.3 (0.9 to 1.8) 0.115 
 
Not including GP practice 
as a random effect 
43% (124/291) 50% (148/295) 1.3 (1.0 to 1.9) 0.079 
 
Adjusted by days since 
randomisation to primary 
outcome assessment 
43% (124/291) 50% (148/295) 1.3 (1.0 to 1.9) 0.094 
All analyses are adjusted by site (Bristol, Sheffield or Southampton) and baseline QRISK2 score. GP 
practice is included as a random effect unless otherwise specified. Analyses are further adjusted by other 
covariates if specified. 
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Table 3 Sub-group analyses of primary outcome  
 Improving or maintaining 
QRISK2 at 12-month follow-up 
Adjusted odds ratioa 
(95% confidence interval) 
Interaction 
P-value 
 Usual care 
N = 291 
Intervention 
N = 295 
  
Baseline CVD assessment 
age group 
    
40-59 54% (7/13) 61% (11/18) 1.5 (0.3 to 6.6)  
60-69 44% (78/177) 49% (75/152) 1.2 (0.8 to 1.9)  
≥70 39% (39/101) 50% (62/125) 1.6 (0.9 to 2.8) 0.708 
Sex     
Male  46% (105/227) 51% (125/243) 1.2 (0.9 to 1.8)  
Female 30% (19/64) 44% (23/52) 1.8 (0.8 to 4.0) 0.369 
Baseline QRISK2 score     
17.3-24.9 37% (37/101) 45% (44/98) 1.4 (0.8 to 2.5)  
25.0-29.9 38% (26/68) 44% (35/79) 1.2 (0.6 to 2.4)  
≥30.0 50% (61/122) 58% (69/118) 1.4 (0.8 to 2.4) 0.947 
Baseline modifiable risk 
factor 
    
Systolic blood pressure <140 33% (30/90) 41% (35/85) 1.5 (0.8 to 2.8)  
Systolic blood pressure ≥140 47% (94/201) 54% (113/210) 1.3 (0.9 to 1.9) 0.726 
Body mass index <30.0 50% (65/131) 52% (67/129) 1.1 (0.6 to 1.8)  
Body mass index ≥30.0 37% (59/160) 49% (81/166) 1.7 (1.1 to 2.6) 0.200 
Current smoker 51% (29/57) 53% (23/43) 1.1 (0.5 to 2.5)  
Not current smoker  41% (95/234) 50% (125/252) 1.4 (1.0 to 2.1) 0.546 
 
 
  
a Odds ratio comparing intervention versus usual care.  
All analyses are adjusted by site (Bristol, Sheffield or Southampton), baseline outcome and baseline QRISK2 score. 
GP practice is included as a random effect. 
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Table 4 Secondary outcomes: QRISK2 score as a continuous outcome and individual 
modifiable cardiovascular risk factors of blood pressure, cholesterol, weight and body mass 
index. 
 Usual care 
N = 296 (6 months); 
291 (12 months) 
 
Intervention 
N = 301 (6 months); 
295 (12 months) 
  
 Unadjusted 
mean (SD) 
N Unadjusted 
mean (SD) 
N Adjusted difference in 
means (95% confidence 
interval) 
P-value 
QRISK2 score as 
continuous variable 
      
6 months 31.0 (9.5) 296 31.4 (10.3) 301 0.1 (-0.2 to 0.4) 0.489 
12 months 31.2 (10.3) 291 31.3 (10.7) 295 -0.4 (-1.2 to 0.3) 0.269 
Systolic blood pressure (mmHg)       
6 months 141.4 (15.4) 296 141.0 (15.1) 301 0.0 (-1.9 to 1.9) 0.997 
12 months 142.2 (16.1) 291 139.6 (14.0) 295 -2.7 (-4.7 to -0.6) 0.011 
Diastolic blood pressure (mmHg)       
6 months 78.0 (9.7) 296 78.2 (9.9) 301 -0.6 (-1.8 to 0.6) 0.337 
12 months 78.7 (9.9) 291 76.6 (9.2) 295 -2.8 (-4.0 to -1.6) <0.001 
Total cholesterol (mmol/L)a      
12 months 4.7 (1.1) 288 4.6 (1.2) 295 -0.1 (-0.2 to 0.0) 0.167 
Total cholesterol/HDL ratio a       
12 months 4.0 (1.5) 287 4.0 (1.7) 294 -0.1 (-0.2 to 0.1) 0.451 
Weight (kg)        
6 months 91.1 (18.4) 296 91.7 (17.7) 301 -0.9 (-1.5 to -0.2) 0.006 
12 months 91.2 (19.1) 291 91.3 (17.5) 293 -1.0 (-1.8 to -0.3) 0.008 
Body mass index (kg/m2)       
6 months 30.6 (5.4) 296 30.7 (5.5) 301 -0.3 (-0.5 to -0.1) 0.006 
12 months 30.8 (5.7) 291 30.5 (5.4) 293 -0.4 (-0.6 to -0.1) 0.008 
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a Cholesterol was not re-measured after 6 months. The baseline cholesterol measurement was used to calculate 
QRISK2 at 6 months. 
HDL = high density lipoprotein.  
All analyses are adjusted by site (Bristol, Sheffield or Southampton), baseline QRISK2 score and baseline outcome. 
GP practice is included as a random effect. 
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Table 5 Secondary outcome: smoking 
 Usual care 
N = 296 (6 
months); 291 
(12 months) 
% (n) 
Intervention  
N = 301 (6 
months); 295 
(12 months) 
% (n) 
Adjusted odds ratio (95% 
confidence interval) 
P-value 
Smoker at 6 months:     
Yes 18% (52/296) 15% (45/301)  N/A N/A 
No   82% (244/296) 85% (256/301) 0.3 (0.1 to 1.2) 0.099 
Smoker at 12 months:     
Yes 18% (52/291) 17% (49/295)  N/A N/A 
No 82% (239/291) 83% (246/295) 0.4 (0.2 to 1.0) 0.061 
All analyses are adjusted by site (Bristol, Sheffield or Southampton), baseline QRISK2 score and by baseline smoking 
category (non-smoker, ex-smoker, light smoker, moderate smoker, heavy smoker). GP practice is included as a 
random effect.  
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Table 6 Secondary outcomes at 12 months follow-up 
 Usual care 
N = 300 
Intervention 
N = 300 
   
 Unadjusted 
mean (SD) 
N Unadjusted 
mean (SD) 
N Adjusted difference in 
means (95% confidence 
interval) 
P-
value 
Quality of life (EQ-5D-5L)32  0.78 (0.2) 297 0.81 (0.2) 295 0.01 (-0.01 to 0.03) 0.410 
Patient behaviours       
Exercise behaviour (heiQ 
subscale ‘Health directed 
behaviour’)a33 
2.9 (0.8)  294  3.0 (0.8)  297  0.1 (0.0 to 0.2)  0.003  
Diet (Starting the Conversation 
questionnaire)a34  
10.3 (2.1) 299  10.9 (2.1) 300  0.6 (0.4 to 0.9) <0.001 
Patient experience       
Satisfaction with treatmenta,b 3.7 (0.8)  215  3.9 (0.7)  244  0.1 (0.0 to 0.3)  0.032  
Satisfaction with amount of 
support receiveda,b 
2.8 (0.6)  207  3.1 (0.5)  260  0.3 (0.2 to 0.4)  <0.001  
Patient perceived access to 
carea,b 
5.5 (1.7)  293  5.8 (1.3)  287  0.3 (0.0 to 0.5)  0.015  
Self-management skills and self- efficacy (heiQ)33     
Self-monitoring and insighta 3.2 (0.4)  295  3.3 (0.4)  295  0.1 (0.0 to 0.1)  0.073  
Constructive attitudes and 
approachesa 
3.3 (0.5)  296  3.4 (0.5)  295  0.0 (0.0 to 0.1)  0.628  
Skill and technique acquisitiona 3.1 (0.5)  297  3.2 (0.5)  295  0.1 (0.1 to 0.2)  <0.001  
Health services navigationa 3.1 (0.6)  296  3.2 (0.5)  297  0.0 (0.0 to 0.1)  0.268  
Medication adherence (Morisky)35 a      
Anti-hypertensivesc 3.8 (0.5)  194  3.9 (0.3)  203  0.1 (0.0 to 0.2)  0.013  
Statinsc 3.6 (0.8)  165  3.8 (0.5)  169  0.2 (0.1 to 0.3)  0.005  
Health literacy (eHEALs)36 a 3.9 (0.7) 296 4.0 (0.7) 295 0.1 (0.0 to 0.2) 0.128 
Care coordination (Haggerty)37     
Role clarity and co-ordinationa 2.9 (0.5)  247  3.0 (0.3)  263  0.1 (0.0 to 0.1)  0.015  
Evidence of a care plana 3.8 (2.1)  209  4.9 (2.0)  236  1.2 (0.8 to 1.5)  <0.001  
Overall experience of organisation 
of healthcare a 
3.6 (0.9)  296  3.8 (0.7)  296  0.1 (0.0 to 0.2)  0.044  
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Self-organisation of healthcare a 3.9 (1.1)  283  3.8 (1.0)  287  -0.1 (-0.2 to 0.1)  0.368  
Use of telehealth a,b,c       
Online searching 1.6 (0.7) 297 1.6 (0.7) 296 0.1 (-0.0 to 0.2) 0.097 
Online forum or group 1.1 (0.3) 295 1.1 (0.4) 298 0.0 (-0.0 to 0.1) 0.289 
All analyses are adjusted by site (Bristol, Sheffield or Southampton), baseline outcome (if measured) and baseline 
QRISK2 score. GP practice is included as a random effect. 
a Higher score is more positive (less access difficulties, greater satisfaction) 
b Based on scales generated prior to the main trial analysis using principal components analysis and incorporating 
questions taken from existing validated questionnaires or constructed for this research. 
C Only applicable to those taking anti-hypertensives or statins respectively 
d 5 level ordered categorical variable (Never/almost never to Daily /almost daily) 
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Table 7 Complier-average causal effect analysis of the primary outcome 
 Maintenance/reduction in 
QRISK2  at 12-month follow-
up 
Partial compliers classified 
as non-compliers 
Partial compliers classified 
as full compliers 
   Intervention vs. Usual Care Intervention vs. Usual Care 
 Usual care 
N=291 
Intervention 
N=293 
Unadjusted odds ratio 
(95% CI) 
Unadjusted odds ratio 
(95% CI) 
Amount of intervention 
received: 
    
None (0-2 encounters) 43% (124/291) 29% (4/14)          
Partial (3-11 encounters)  44% (77/177)   
Full (12-13 encounters)  65% (66/102) 2.4 (1.4 to 4.3) 1.4 (1.0 to 1.9) 
Three participants who never received the Healthlines intervention and two participants who only received unscheduled non-
encounter calls are categorised as receiving none of the intervention. Two intervention arm participants have missing 
encounter data.  
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Table 8 Treatment optimisation: cardiovascular risk-related medication prescriptions over the 
trial 
 
 Usual care 
N  = 316 
Intervention 
N = 325 
Intervention vs. Usual care 
 % Participants 
(n) 
% Participants 
(n) 
Adjusted odds ratio 
(95% CI) 
P-value 
Experienced at least one change in medication over 12 month period (medical records data) 
Antihypertensive 32% 100/316 38% 123/325 1.3a (0.9 to 1.8)                                                                                                                                         0.117 
Cholesterol drugs 
including statins 
22% 71/316 26% 84/325 1.2a (0.8 to 1.7) 
 
0.327 
Self-reported use of  medication over 12 month period (questionnaire data) 
Antihypertensive 68% 196/289 70% 202/287   
Statin 57% 165/297 57% 166/290   
Prescribed at least one medication over trial period (medical records data) 
Antiplatelet 18% 57/316 19% 62/325   
Cholesterol drugs 
including statins 
61% 192/316 62% 201/325   
Smoking cessation 1% 3/316 2% 5/325   
Obesity medication 1% 2/316 1% 4/325   
Antihypertensive 70% 222/316 73% 236/325   
Prescribed antihypertensive drug by drug class over trial period (medical records data) 
ACE inhibitors or 
ARBs 
50% 159/316 52% 170/325   
Beta blockers 18% 58/316 16% 52/325   
Calcium blockers 36% 114/316 40% 129/325   
Diuretics 29% 90/316 29% 93/325   
Other 8% 26/316 8% 26/325   
 
ACE inhibitors = Angiotensin-converting-enzyme inhibitor, ARBs = Angiotensin receptor blockers.  
 
a Only these between treatment-group comparisons are analysed because treatment optimisation was a key aspect of the 
intervention. Analyses are adjusted by site (Bristol, Sheffield or Southampton) and baseline QRISK2 score. GP practice is 
included as a random effect. 
